%0 Journal Article
%A Kohle, Felix
%A Wunderlich, Gilbert
%A Fink, Gereon R.
%A Schroeter, Michael
%A Lehmann, Helmar C.
%A Schneider, Christian
%T Rituximab in non-systemic vasculitic neuropathy: a single-center experience
%J Journal of neurology
%V 271
%N 7
%@ 0367-004X
%C Heidelberg
%I Springer
%M FZJ-2024-03585
%P 4406 - 4411
%D 2024
%Z Funding Open Access funding enabled and organized by Projekt DEAL. FK was supported by the Cologne Clinician Scientist Program (CCSP)/Faculty of Medicine/University of Cologne. Funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) (Project No. 413543196).
%X Objectives This case series reports clinical features and outcome of four patients with non-systemic vasculitic neuropathy(NSVN) treated with the anti-CD20 agent rituximab.Methods Clinical, electrophysiological and biopsy data were retrospectively obtained and evaluated. Only patients withpathological definite or probable NSVN were included. Extensive clinical and laboratory work-up excluded systemic vasculitis.Follow-up data for at least 12 months and up to five years is provided. Outcome of the patients was assessed usingthe MRC-Sum Score, Prineas Score and Neurological Symptom Score.Results Two of four patients treated with rituximab achieved disease remission and one patient remained stable under anti-CD20 therapy after a required treatment switch due to toxic side effects of cyclophosphamide. One patient deteriorated underrituximab induction. Rituximab was well tolerated in all patients.Discussion Anti-CD20 therapy might be an alternative in NSVN patients requiring further treatment escalation or treatmentswitch due to side effects of corticosteroids or cyclophosphamide.
%F PUB:(DE-HGF)16
%9 Journal Article
%$ 38656623
%U <Go to ISI:>//WOS:001208272700002
%R 10.1007/s00415-024-12378-1
%U https://juser.fz-juelich.de/record/1027019